{"id":54908,"date":"2025-01-28T08:29:25","date_gmt":"2025-01-28T08:29:25","guid":{"rendered":"https:\/\/www.innovationnewsnetwork.com\/?p=54908"},"modified":"2025-01-28T08:29:25","modified_gmt":"2025-01-28T08:29:25","slug":"oral-antibodies-for-prophylactic-treatment-of-enteric-infectious-diseases","status":"publish","type":"post","link":"https:\/\/www.innovationnewsnetwork.com\/oral-antibodies-for-prophylactic-treatment-of-enteric-infectious-diseases\/54908\/","title":{"rendered":"Oral antibodies for prophylactic treatment of enteric infectious diseases"},"content":{"rendered":"

Antimicrobial resistance (AMR) is a top ten public threat to human health. Immuron<\/a> is developing innovative colostrum-based oral antibodies to treat infectious diseases without the use of antibiotics.<\/h2>\n

Australian biopharmaceutical company Immuron has developed a platform technology that generates highly specific colostrum-based antibodies to prevent and\/or treat enteric diseases without the issues associated with antibiotics.<\/p>\n

Orally-delivered antibodies specifically target enteric pathogens in the GI tract, preventing their attachment to the intestinal wall. Immuron\u2019s oral-targeted therapeutics offer significant advantages over intravenous administration due to their lack of systemic absorption into the blood stream, targeting the drug to the GI tract to rapidly neutralise and clear the infection.<\/p>\n

The key ingredient used, bovine colostrum, is a natural product containing no artificial additives or nutrients, and has a high safety profile.<\/p>\n

Travelan<\/h3>\n

Immuron\u2019s flagship commercial product, Travelan\u00ae, targets multiple strains of enterotoxigenic E. coli (ETEC) \u2013 the major cause of \u2018Travellers\u2019 diarrhoea\u2019. Clinical studies have demonstrated 84% to >90% protective efficacy in preventing ETEC-attributable diarrhoea in two clinical studies.\u00b9<\/p>\n

\"\"<\/p>\n

Testing for new drug candidates<\/h3>\n

Immuron\u2019s pipeline includes several drug candidates at various stages of pre-clinical and clinical development.<\/p>\n

In collaboration with Dr Dena Lyras and her team at Monash University, Immuron is developing IMM-529 as an adjunctive therapy for the prevention and\/or treatment of recurrent Clostridioides difficile infection (CDI). IMM-529 targets Toxin B (TcB), the spores and the surface layer proteins of the vegetative cells. This unique three-target approach has yielded promising results in pre-clinical infection and relapse models, including:<\/p>\n